ASTRAZENECA PLC

AZNNYSE

Earnings Oct 30US Equity

$158.75▼ $3.10 (−1.95%)

Live

1h—

24h▼ 1.9%

7d▼ 1.7%

14d▼ 8.4%

30d▼ 6.4%

1y—

🏦Market Cap

$246.22B

Large Cap

📈Revenue Growth (YoY)

+8.6%

Slowing

📊Gross Margin

81.3%

High

💵FCF Margin

12.6%

Healthy

⚖️P/S Ratio

4.1x

Fair

Otter Score

Weak

Trading Snapshot

Day Range: $157.11 – $160.30
52-Week Range: $10,784.00 – $15,730.00
Volume: $4.19B
Avg Volume: $3.67B
Shares Outstanding: 1.55B
Next Earnings: Sep 10, 2026

Fundamentals Snapshot

Annual Revenue: $58.74B
Last Q Revenue: $15.38B
P/E Ratio: 23.8
P/S Ratio: 4.1x
EPS (TTM): $6.69
Dividend Yield: 1.97%

Why Investors Own AZN

✓High-growth profile — revenue up +33.1% YoY with expanding US Equity exposure.
✓Healthy economics — 66% gross margin and 17% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$58.74B▲ +28.4% YoY

Gross Margin (TTM)

66.2%▲ +0.0% YoY

Operating Income (TTM)

$17.86B▲ +28.4% YoY

Free Cash Flow (TTM)

$9.69B▲ +28.4% YoY

About ASTRAZENECA PLC

AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.

🦦